Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report issued on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright initiated coverage on Vanda Pharmaceuticals in a report on Thursday, October 31st. They set a “buy” rating and a $18.00 price objective on the stock.

Vanda Pharmaceuticals Price Performance

Shares of Vanda Pharmaceuticals stock opened at $4.60 on Wednesday. Vanda Pharmaceuticals has a 1-year low of $3.46 and a 1-year high of $6.75. The business has a 50-day moving average of $4.84 and a 200-day moving average of $5.24. The company has a market capitalization of $268.22 million, a PE ratio of -16.43 and a beta of 0.76.

Insiders Place Their Bets

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the transaction, the director now owns 44,857 shares of the company’s stock, valued at $231,910.69. This trade represents a 10.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 8.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Meeder Asset Management Inc. acquired a new position in Vanda Pharmaceuticals in the second quarter valued at approximately $39,000. ORG Wealth Partners LLC bought a new position in Vanda Pharmaceuticals during the 3rd quarter worth $40,000. China Universal Asset Management Co. Ltd. increased its position in Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 4,374 shares during the period. SG Americas Securities LLC bought a new stake in Vanda Pharmaceuticals in the second quarter valued at $61,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Vanda Pharmaceuticals by 18.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 2,425 shares during the period. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.